Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 16/20 | 0.64 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6463848 | 0.88 | AHR (0.60) | AHRCDK1CCNB1ALDH1A1 | |
| SCHEMBL8134191 | 0.85 | AHR (0.57) | AHRCDK1CCNB1ALDH1A1 | |
| SCHEMBL9215395 | 0.84 | AHR (0.73) | AHR | |
| SCHEMBL7202544 | 0.80 | AHR (0.59) | AHRCDK1CCNB1MAOB | |
| SCHEMBL1804174 | 0.78 | AHR (1.00) | AHR | |
| SCHEMBL1803931 | 0.77 | AHR (0.68) | AHRPOLB | |
| SCHEMBL29375526 | 0.77 | AHR (0.68) | AHRPOLB | |
| SCHEMBL8120005 | 0.74 | AHR (0.64) | AHR | |
| SCHEMBL6472813 | 0.74 | AHR (0.64) | AHRMAOB | |
| SCHEMBL2281295 | 0.73 | AHR (1.00) | AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608306-A2 | ALKYL-SUBSTITUTED PCDF AS A TREATMENT FOR PROSTATE CANCER | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2005-12-28 | — | — | EP | claimed |
| US-20050143450-A1 | Alkyl PCDF as a treatment for prostate cancer | TEXAS A&M UNIVERSITY SYSTEM (US) | 2005-06-30 | — | — | US | claimed |
| WO-2005032452-A2 | ALKYL-SUBSTITUTED PCDF AS A TREATMENT FOR PROSTATE CANCER | TEXAS A & M UNIVERSITY SYSTEM (US) | 2005-04-14 | — | — | WO | claimed |
| EP-1140047-B1 | ENDOCRINE THERAPY FOR BREAST CANCER: COMBINED TREATMENT WITH TAMOXIFEN PLUS ALKYL PCDFS | TEXAS A & M UNIV SYS (US) | 2003-10-29 | — | — | EP | claimed |
| EP-1140047-A2 | ENDOCRINE THERAPY FOR BREAST CANCER: COMBINED TREATMENT WITH TAMOXIFEN PLUS ALKYL PCDFS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2001-10-10 | — | — | EP | claimed |
| US-6136845-A | ANTITUMOR AGENTS; MIXTURE CONTAINING POLYCHLORINATED DIBENZOFURAN | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2000-10-24 | — | — | US | claimed |
| WO-2000037065-A2 | ENDOCRINE THERAPY FOR BREAST CANCER: COMBINED TREATMENT WITH TAMOXIFEN PLUS ALKYL PCDFS | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2000-06-29 | — | — | WO | claimed |
| US-5516790-A | Synthesis and application of alkyl-substituted dibenzofurans as antitumorigenic agents | TEXAS A&M UNIVERSITY SYSTEM TECHNOLOGY LICENSING OFFICE (US) | 1996-05-14 | — | — | US | claimed |
| EP-1608306-A2 | ALKYL-SUBSTITUTED PCDF AS A TREATMENT FOR PROSTATE CANCER | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050143450-A1 | Alkyl PCDF as a treatment for prostate cancer | TEXAS A&M UNIVERSITY SYSTEM (US) | 2005-06-30 | — | — | US | disclosed |
| WO-2005032452-A2 | ALKYL-SUBSTITUTED PCDF AS A TREATMENT FOR PROSTATE CANCER | TEXAS A & M UNIVERSITY SYSTEM (US) | 2005-04-14 | — | — | WO | disclosed |
| EP-1140047-B1 | ENDOCRINE THERAPY FOR BREAST CANCER: COMBINED TREATMENT WITH TAMOXIFEN PLUS ALKYL PCDFS | TEXAS A & M UNIV SYS (US) | 2003-10-29 | — | — | EP | disclosed |
| US-6140063-A | USE OF THE ARYL HYDROCARBON (AH) RECEPTOR PROTEIN COMPLEX AS A DRUG TARGET, ALONE OR IN COMBINATION WITH ANOTHER COMPOUND, TO TREAT CYTOPATHIC CELL CHANGES AND VIRAL INFECTIONS GENERALLY | PARACELSIAN, INC. (US) | 2000-10-31 | — | — | US | disclosed |
| US-6136845-A | ANTITUMOR AGENTS; MIXTURE CONTAINING POLYCHLORINATED DIBENZOFURAN | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2000-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143450-A1 | Alkyl PCDF as a treatment for prostate cancer | KLK3, ACP3, AR | AHR 379/4885CDK1 1797/4885CCNB1 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.